Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid-Results from the ToFingo Successor Study
Lisa Lohmann, Claudia Janoschka, Andreas Schulte-Mecklenbeck, Svenja Klinsing, Lucienne Kirstein, Uta Hanning, Timo Wirth, Tilman Schneider-Hohendorf, Nicholas Schwab, Catharina C Gross, Maria Eveslage, Sven G Meuth, Heinz Wiendl, Luisa Klotz, Lisa Lohmann, Claudia Janoschka, Andreas Schulte-Mecklenbeck, Svenja Klinsing, Lucienne Kirstein, Uta Hanning, Timo Wirth, Tilman Schneider-Hohendorf, Nicholas Schwab, Catharina C Gross, Maria Eveslage, Sven G Meuth, Heinz Wiendl, Luisa Klotz
Abstract
Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the precise consequences of targeting immune cell trafficking for immunoregulatory network functions are only incompletely understood. In the present study, we performed an in-depth longitudinal characterization of functional and phenotypic immune signatures in peripheral blood (PB) and cerebrospinal fluid (CSF) of 15 MS patients during switching from long-term NAT to FTY treatment after a defined 8-week washout period within a clinical trial (ToFingo successor study; ClinicalTrials.gov: NCT02325440). Unbiased visualization and analysis of high-dimensional single cell flow-cytometry data revealed that switching resulted in a profound alteration of more than 80% of investigated innate and adaptive immune cell subpopulations in the PB, revealing an unexpectedly broad effect of trafficking drugs on peripheral immune signatures. Longitudinal CSF analysis demonstrated that NAT and FTY both reduced T cell subset counts and proportions in the CSF of MS patients with equal potency; NAT however was superior with regard to sequestering non-T cell populations out of the CSF, including B cells, natural killer cells and inflammatory monocytes, suggesting that disease exacerbation in the context of switching might be driven by non-T cell populations. Finally, correlation of our immunological data with signs of disease exacerbation in this small cohort suggested that both (i) CD49d expression levels under NAT at the time of treatment cessation and (ii) swiftness of FTY-mediated effects on immune cell subsets in the PB together may predict stability during switching later on.
Keywords: cerebrospinal fluid; fingolimod; immunoregulatory network; multiple sclerosis; natalizumab; spanning-tree progression analysis of density-normalized events; viSNE.
Figures
References
- Steinman L. Weighing in on autoimmune disease: ‘Hub-and-spoke’ T cell traffic in autoimmunity. Nat Med (2013) 19:139–41.10.1038/nm.3088
- Lécuyer M-A, Kebir H, Prat A. Glial influences on BBB functions and molecular players in immune cell trafficking. Biochim Biophys Acta (2016) 1862:472–82.10.1016/j.bbadis.2015.10.004
- Lopes Pinheiro MA, Kooij G, Mizee MR, Kamermans A, Enzmann G, Lyck R, et al. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke. Biochim Biophys Acta (2016) 1862:461–71.10.1016/j.bbadis.2015.10.018
- Schneider-Hohendorf T, Rossaint J, Mohan H, Böning D, Breuer J, Kuhlmann T, et al. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J Exp Med (2014) 211:1833–46.10.1084/jem.20140540
- Koudriavtseva T, Sbardella E, Trento E, Bordignon V, D’Agosto G, Cordiali-Fei P. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab. Clin Exp Immunol (2014) 176:320–6.10.1111/cei.12261
- Francis G, Kappos L, O’Connor P, Collins W, Tang D, Mercier F, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler (2014) 20:471–80.10.1177/1352458513500551
- Berger B, Baumgartner A, Rauer S, Mader I, Luetzen N, Farenkopf U, et al. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. J Neuroimmunol (2015) 282:118–22.10.1016/j.jneuroim.2015.03.022
- Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol (2016) 73:790–4.10.1001/jamaneurol.2016.0826
- Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol (2014) 261:1170–7.10.1007/s00415-014-7325-8
- Kivisakk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, Weiner HL, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology (2009) 72:1922–30.10.1212/WNL.0b013e3181a8266f
- Serpero LD, Filaci G, Parodi A, Battaglia F, Kalli F, Brogi D, et al. Fingolimod modulates peripheral effector and regulatory T cells in MS patients. J Neuroimmune Pharmacol (2013) 8:1106–13.10.1007/s11481-013-9465-5
- Kappos L, Radue E-W, Comi G, Montalban X, Butzkueven H, Wiendl H, et al. Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. Neurology (2015) 85:29–39.10.1212/WNL.0000000000001706
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 69:292–302.10.1002/ana.22366
- Grützke B, Hucke S, Gross CC, Herold MV, Posevitz-Fejfar A, Wildemann BT, et al. Fingolimod treatment promotes regulatory phenotype and function of B cells. Ann Clin Transl Neurol (2015) 2:119–30.10.1002/acn3.155
- Sgier L, Freimann R, Zupanic A, Kroll A. Flow cytometry combined with viSNE for the analysis of microbial biofilms and detection of microplastics. Nat Commun (2016) 7:11587.10.1038/ncomms11587
- Amir el-AD, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol (2013) 31:545–52.10.1038/nbt.2594
- Finak G, Jiang W, Krouse K, Wei C, Sanz I, Phippard D, et al. High-throughput flow cytometry data normalization for clinical trials. Cytometry A (2014) 85:277–86.10.1002/cyto.a.22433
- Levine JH, Simonds EF, Bendall SC, Davis KL, Amir E-AD, Tadmor MD, et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell (2015) 162:184–97.10.1016/j.cell.2015.05.047
- Anchang B, Hart TD, Bendall SC, Qiu P, Bjornson Z, Linderman M, et al. Visualization and cellular hierarchy inference of single-cell data using SPADE. Nat Protoc (2016) 11:1264–79.10.1038/nprot.2016.066
- Qiu P. Toward deterministic and semiautomated SPADE analysis. Cytometry A (2017) 91:281–9.10.1002/cyto.a.23068
- Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology (2008) 71:1261–7.10.1212/01.wnl.0000327609.57688.ea
- Blumenfeld S, Staun-Ram E, Miller A. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFbeta in patients with Multiple sclerosis. J Autoimmun (2016) 70:40–51.10.1016/j.jaut.2016.03.012
- Defer G, Mariotte D, Derache N, Toutirais O, Legros H, Cauquelin B, et al. CD49d expression as a promising biomarker to monitor natalizumab efficacy. J Neurol Sci (2012) 314:138–42.10.1016/j.jns.2011.10.005
- Puñet-Ortiz J, Hervás-García JV, Teniente-Serra A, Cano-Orgaz A, Mansilla MJ, Quirant-Sánchez B, et al. Monitoring CD49d receptor occupancy: a method to optimize and personalize natalizumab therapy in multiple sclerosis patients. Cytometry B Clin Cytom (2018) 94:327–33.10.1002/cyto.b.21527
- Skarica M, Eckstein C, Whartenby KA, Calabresi PA. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol (2011) 235:70–6.10.1016/j.jneuroim.2011.02.010
- Kappos L, Mehling M, Arroyo R, Izquierdo G, Selmaj K, Curovic-Perisic V, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology (2015) 84:872–9.10.1212/WNL.0000000000001302
- Gajofatto A, Bianchi MR, Deotto L, Benedetti MD. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. Eur Neurol (2014) 72:173–80.10.1159/000361044
- Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, et al. Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study. Neurology (2016) 86:771–8.10.1212/WNL.0000000000002395
- Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV. The evidence for a role of B cells in multiple sclerosis. Neurology (2012) 78:823–32.10.1212/WNL.0b013e318249f6f0
- Chuluundorj D, Harding SA, Abernethy D, La Flamme AC. Expansion and preferential activation of the CD14(+)CD16(+) monocyte subset during multiple sclerosis. Immunol Cell Biol (2014) 92:509–17.10.1038/icb.2014.15
- Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord (2017) 10:51–66.10.1177/1756285616666741
- Song Z-Y, Yamasaki R, Kawano Y, Sato S, Masaki K, Yoshimura S, et al. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. PLoS One (2014) 10:e0124923.10.1371/journal.pone.0124923
- Nakamura M, Matsuoka T, Chihara N, Miyake S, Sato W, Araki M, et al. Differential effects of fingolimod on B-cell populations in multiple sclerosis. Mult Scler (2014) 20:1371–80.10.1177/1352458514523496
- Claes N, Dhaeze T, Fraussen J, Broux B, van Wijmeersch B, Stinissen P, et al. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study. PLoS One (2014) 9:e111115.10.1371/journal.pone.0111115
- Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci (2015) 16:16414–39.10.3390/ijms160716414
- Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 66:460–71.10.1002/ana.21867
- Havari E, Turner MJ, Campos-Rivera J, Shankara S, Nguyen T-H, Roberts B, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Immunology (2014) 141:123–31.10.1111/imm.12178
- Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol (2013) 191:5867–74.10.4049/jimmunol.1301926
- Pfender N, Martin R. Daclizumab (anti-CD25) in multiple sclerosis. Exp Neurol (2014) 262(Pt A):44–51.10.1016/j.expneurol.2014.04.015
- Haas J, Schwarz A, Korporal-Kuhnke M, Jarius S, Wildemann B. Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis. J Neuroimmunol (2016) 301:53–60.10.1016/j.jneuroim.2016.10.007
- Adikari SB, Pettersson A, Soderstrom M, Huang Y-M, Link H. Interleukin-10-modulated immature dendritic cells control the proinflammatory environment in multiple sclerosis. Scand J Immunol (2004) 59:600–6.10.1111/j.1365-3083.2004.01453.x
- Lattanzi S, Danni M, Cerqua R, Taffi R, Provinciali L, Silvestrini M. Prediction of disability progression in fingolimod-treated patients. J Neurol Sci (2015) 358:432–4.10.1016/j.jns.2015.09.010
- Kalincik T, Brown JW, Robertson N, Willis M, Scolding N, Rice CM, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol (2017) 16:271–81.10.1016/S1474-4422(17)30007-8
Source: PubMed